Conference Reports for NATAP

Back

60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2009     Response-Guided Therapy for Boceprevir Combination Treatment? Results from HCV SPRINT-1 - (04/26/10)   High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon α-2b + Ribavirin When Treated with Boceprevir Combination Therapy - Results From HCV Sprint-1 - (04/26/10)   Combination of IDX184, a Nucleotide Prodrug Polymerase Inhibitor, with Other Classes of HCV Inhibitors is Additive to Synergistic in the HCV Replicon in vitro - (12/21/09)   Parenchymal Fibrosis and Cancer Specific Outcomes Following Liver Resection in Patients with HBV Associated Hepatocellular Carcinoma - (12/10/09)   Prevalence and Characteristics of Hepatitis B Virus Mutations in Chronic Hepatitis B Patients on Oral Antiviral Therapy: The CHARM Study - (12/07/09)   Asian and White Patients With Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon (PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of the REDD 2/3 Study - (12/07/09)   Identifying HCV genotype 2/3 patients who could receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin - (12/07/09)   Ribavirin priming enhances efficacy of chronic hepatitis C re-treatment in patients who had not responded to previous combination therapy - (12/07/09)   PREDICT Study Final Results: Efficacy and Safety of 24-Wk Regimen of Peginterferon alfa-2b Plus Weight-based Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 (G1) With Low Viral Load Who Achieve Rapid Viral Response - (12/07/09)   Standard versus higher induction doses of peginterferon alfa-2a (40KD) and/or higher ribavirin (RBV) in HCV G1 patients with high viral load and body weight ≥85 kg: Final results of the PROGRESS study - (12/02/09)   Higher Sustained Post-Treatment Virologic Response Following Peginterferon Alfa-2a ± Adefovir Compared With Adefovir Monotherapy in HBeAg-Positive Patients - (12/02/09)   Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (12/02/09)   Diagnosis and Management of Chronic Hepatitis B in Asian-American Patients Among Primary Care Physicians in the United States - (12/02/09)   Adherence to AASLD Guideline Recommendations for Laboratory Monitoring of Chronic Hepatitis B Patients Who are Not Receiving Antiviral Treatment - (12/02/09)   HBsAg Decline in HBeAg-Negative Patients Treated With Peginterferon Alfa-2a is Associated With Sustained Response up to 5 Years Post-Treatment: Patients with Continuous HBsAg Decline Starting Before Week 24 Achieve Highest Rates of Response - (12/01/09)   A Finite Course of Peginterferon Alfa-2a Results in Inactive Chronic Hepatitis B and HBsAg Clearance 5 Years Post-Treatment in Patients With HBeAg-Negative Disease: Baseline Characteristics and Predictive Factors of Long-Term Response - (12/01/09)   HBsAg Clearance Continues to Increase Post-Treatment in Patients with HCV/HBV Coinfection Treated With Peginterferon Alfa-2a Plus Ribavirin: 1.5 Year Follow up - (12/01/09)   Extended Treatment With Peginterferon Alfa-2a Benefits Patients With HBeAg-Positive Chronic Hepatitis B With a Partial Response After 48 Weeks of Therapy - Clinical Experience From a Chinese Center - (12/01/09)   Extending Peginterferon Alfa-2a Therapy in Patients With HBeAg-Positive Chronic Hepatitis B Who Did Not Achieve a Response at Week 48 Can Lead to HBeAg Seroconversion and HBsAg Clearance - (12/01/09)   On-Treatment Quantification of HBsAg in Difficult-to-Treat Patients With Lamivudine Resistance Can Help Identify Those Most Likely to Achieve Sustained Post-Treatment Response to Peginterferon Alfa-2a Rescue Therapy - (12/01/09)   SVR Results of Weight-based Taribavirin Versus Weight-based Ribavirin, Both with Peginterferon alfa-2b, in Naïve Chronic Hepatitis C, Genotype 1 Patients - (11/30/09)   SVR Results of Weight-based Taribavirin Versus Weight-based Ribavirin, Both with Peginterferon alfa-2b, in Naïve Chronic Hepatitis C, Genotype 1 Patients - (11/30/09)   Physician Country of Birth and Hepatitis B Virus (HBV) Screening Practices of Asian-American Primary Care Providers (PCPs) Who Treat Asian Adults Living in the US - (11/30/09)   Tenofovir Disoproxil Fumarate-Containing Regimens in Pregnancy: Report From the Antiretroviral Pregnancy Registry - (11/30/09)   Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase - (11/30/09)   Three Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B - (11/30/09)   In Vitro Tenofovir Sensitivity of HBV Populations from Clinical Specimens Containing rtA181T/V and/or rtN236T - (11/30/09)   TENOFOVIR (TDF) IS EFFECTIVE IN LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B PATIENTS WHO HARBOUR rtA194T AT BASELINE - (11/30/09)   Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naïve patients with chronic hepatitis C genotype 1 - (11/10/09)   Entecavir and Tenofovir combination therapy in chronic Hepatitis B: Rescue therapy in patients with advanced fibrosis and multiple previous treatment failures. Results from an international multicenter cohort study. - (11/10/09)   High rates of HBeAg seroconversion and HBsAg loss with Tenofovir + Emtricitabine in patients with HBV-HIV co-infection irrespective of CD4+ cell count - (11/10/09)   Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Patients with Genotype 1 Hepatitis C: Final Results - (11/10/09)   Loss of HBsAg in Nucleoside-Naïve HBeAg(+) Chronic Hepatitis B Patients Following Treatment with Entecavir or Lamivudine: Evaluation of HBV Genotypes - (11/10/09)   Long-term Follow-up Evaluation of the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in a European Multicenter (Nucleos(t)ide Experienced) Hepatitis B Virus HBV-infected Cohort - (11/10/09)   Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from a large multicenter cohort study in 376 patients - (11/10/09)   Telaprevir Vertex hep C protease inhibitor drug works well in twice daily dosing - (11/10/09)   More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens - press release from Vertex - (11/10/09)   2 Oral HCV Drug Combination R7227+R7128 Without Interferon/ribavirin in INFORM Study - (11/09/09)   SVR Improves Survival, Risk for Liver Cancer, Decompensated Liver Disease and Liver Transplant/Death - Also, Transient Viral Suppression (breakthroughs/relapsers) Improves Clinical Outcomes Too - (11/09/09)   KINETIC ANALYSIS OF VIRAL REBOUND AND DRUG-RESISTANT VIRAL VARIANT DYNAMICS IN PATIENTS TREATED WITH ITMN-191 (RG7227) MONOTHERAPY SUGGESTS A HIGH BARRIER TO VIRAL ESCAPE - (11/09/09)   INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2a/RIBAVIRIN - (11/09/09)   Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in "Difficult-to-Cure" Patients With Chronic Hepatitis C (CHC): a Pooled Analysis From the PROVE1 and PROVE2 Trials - (11/09/09)   Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/06/09)   Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) With Chronic Hepatitis B (Study 103) - (11/06/09)   Resistance Surveillance for up to 144 Weeks in HBeAg+ and HBeAg- Hepatitis B Patients Treated with Tenofovir DF Showed No Relationship Between Virologic Breakthrough and Emergence of Genotypic Changes in HBV Polymerase - (11/06/09)   A Phase 2, Double-Blind, Randomized Study Comparing The Safety of Tenofovir Disoproxil Fumarate (TDF), Emtricitabine Plus TDF (Truvada, TVD) and Entecavir (ETV) in Subjects with Decompensated Chronic Hepatitis B Liver Disease - (11/06/09)   Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States - (11/06/09)   Telaprevir PROVE3 Final Results: treatment-experienced patients - (11/06/09)   HCV Response Linked Strongly to Gene Variant IL28B - (11/06/09)   HCV antibody seroconversion in a U.S. HIV-infected male clinical trials population - (11/06/09)   SILEN-C1: Early Antiviral Activity and Safety of BI 201335 Combined with Peginterferon alfa-2a and Ribavirin in Treatment-naïve Patients with Chronic Genotype 1 HCV infection - (11/06/09)   Treatment-naïve, genotype-1 HCV-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone - (11/06/09)   HCV Sex Transmission Among HIV+ MSM in NYC Study Report from Mt Sinai Researchers - (11/06/09)   Genotypic and Phenotypic Analysis of Samples From HCV-Infected Subjects Treated with BMS-650032 in a Single Ascending Dose Study - (11/06/09)   Early Viral Response Rates in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Infection Treated with MK-7009, a Novel NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days - (11/05/09)   Safety and Antiviral Activity of NS5B Polymerase Inhibitor MK-3281in Genotype 1 and 3 HCV-Infected Patients - (11/05/09)   COMBINATION THERAPY WITH NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITORS IN GENOTYPE 1 HCV INFECTED PATIENTS: INTERIM RESISTANCE ANALYSIS OF INFORM-1 COHORTS A-D - (11/05/09)   Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype 1 who had previous exposure to TMC435 - (11/05/09)   A Phase 1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-rIL-29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection - (11/05/09)   Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection - (11/05/09)   PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) OF COMBINATION RG7227 AND RG7128 THERAPY FROM INFORM-1 DEMONSTRATES SIMILAR EARLY HCV VIRAL DYNAMICS WHEN RG7227 IS COMBINED WITH EITHER PEG-IFN/RIBAVIRIN (SOC) OR RG7128 - (11/05/09)   Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/05/09)   Merck HCV Protease MK-7009 - (11/05/09)   HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)   Combination Therapy With A Nucleoside Polymerase (RG7128) And Protease (RG7227/ITMN-191) Inhibitor In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (11/04/09)   Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS- 650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection - (11/04/09)   High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon α-2b + Ribavirin When Treated with Boceprevir Combination Therapy Results From HCV Sprint-1 - (11/04/09)   Once Daily Narlaprevir (SCH 900518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study - (11/04/09)   BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C - (11/04/09)   Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Schering Plough press release - (11/01/09)   Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C - (11/01/09) Schering Plough press release   GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15% - (11/01/09) press release   Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin - (11/01/09)   Schering hep C drug promising in Phase II study - (11/01/09)   Telaprevir PROVE3 Final Results: treatment-experienced patients - (11/01/09)   Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/01/09)   Merck HCV Protease MK-7009 - (11/01/09)   HBsAg Decline in HBeAg-Negative Patients Treated With Peginterferon Alfa-2a is Associated With Sustained Response up to 5 Years Post-Treatment: Patients with Continuous HBsAg Decline Starting Before Week 24 Achieve Highest Rates of Response - (11/01/09)